Which companies are Cuorips's closest peers?

The cockpit's peer set: Alector (ALEC), Fennec Pharmaceuticals (FENC), ProKidney (PROK), Benitec Biopharma (BNTC), AP Biosciences (6945.TWO), Viva Biotech (1873.HK), Laekna (2105.HK), IMPACT Therapeutics (7630.HK).

Is Cuorips expensive compared with its peers?

On ev / sales it trades at 392.1× against a peer median of 10.7×, 4th most expensive of 17 in its peer set.

How has Cuorips stock performed?

Over six months to 6 Nov 2026 the shares returned -9.2% against -28.2% for the median peer; over one year -10.9%.

← CockpitCompetitor Analysis › 4894.T Cuorips Inc.Open in the cockpit ↗

Cuorips Inc.4894.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Biotechnology

Momentum leader 80

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$341M

US dollars, full cap

Free float

70%

of shares outstanding

$/day

$7.40M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-78.5 pp

WACC 5.0%

Hurdle

n/a

no reverse DCF

Next earnings

7 days

13 Nov 2026

Close · JPY¥6,050

1D-7.6%

1W-17.7%

1M-6.9%

3M+33.4%

6M-9.2%

YTD+0.3%

1Y-10.9%

ATR %6.9%

52w lowhigh51.2% off high

What Cuorips does

Employees: 51

Cuorips at a glance

Size Cuorips (4894.T) is a Japan Health Care company (Biotechnology) with a market value of $341M, the 1278th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥6,050 on 6 Nov 2026.

Performance Over six months the shares fell 9.2%, against -28.2% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th highest of 18 in its peer set.

Growth Revenue fell 50.6% over the last twelve months (peer median +7.0%); the operating margin is -947.3% (peer median -279.2%).

Valuation It trades at 392.1× enterprise value to sales against a peer median of 10.7× (4th most expensive of 17).

Capital Return on invested capital runs 78.5 points below its cost of capital (5.0% WACC).

Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Cuorips against the median of its 20 peers (local-currency closes).

Cuorips financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	¥129M	¥212M	¥175M	¥23.1M	¥38.3M
Revenue growth	—	+21%	+658%	-40%	—
Gross profit	¥5.13M	¥45.9M	¥91.6M	-¥60.5M	-¥57.6M
EBITDA	-¥1.12B	-¥997M	-¥514M	-¥518M	-¥372M
Net income	-¥1.14B	-¥1.02B	-¥644M	-¥632M	-¥452M
Free cash flow	n/a	-¥1.10B	-¥893M	-¥475M	-¥407M
Capital expenditure	n/a	¥49.8M	¥89.8M	¥35.9M	¥10.6M
Total debt	¥0	¥0	¥0	¥0	¥0

Quarterly statements and history in the cockpit →

Cuorips competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Cuorips is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cuorips is the large dot.

Cuorips competitors and peer comparison

How Cuorips compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cuorips against its 20 peers (data as of 6 Nov 2026)
Measure	4894.T	Peer median	Rank in peer set
1-month return	-6.9%	-13.7%	8th highest of 20
6-month return	-9.2%	-28.2%	5th highest of 18
Distance from 52-week high	-51.2%	-54.6%	7th highest of 20
Revenue growth (TTM)	-50.6%	+7.0%	6th lowest of 16
Operating margin	-947.3%	-279.2%	5th lowest of 17
EV / Sales	392.1×	10.7×	4th most expensive of 17
ROIC minus cost of capital	-78.5 pp	-10.0 pp	4th lowest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Cuorips 4894.T	Japan	$341M	-9%	-51%	-947%	392.1×	n/a	n/a
Alector ALEC	United States	$340M	+9%	-83%	-857%	14.4×	n/a	n/a
Fennec Pharmaceuticals FENC	United States	$344M	+42%	+78%	-3%	5.1×	n/a	n/a
ProKidney PROK	United States	$345M	-39%	+55%	-21,665%	1,556.3×	n/a	n/a
Benitec Biopharma BNTC	United States	$333M	-22%	n/a	n/a	n/a	n/a	n/a
AP Biosciences 6945.TWO	Taiwan	$330M	-32%	-100%	n/a	n/a	n/a	n/a
Viva Biotech 1873.HK	Hong Kong	$354M	-14%	+7%	10%	1.2×	5.6%	+19.1%
Laekna 2105.HK	Hong Kong	$328M	-57%	n/a	-57%	4.8×	n/a	n/a
IMPACT Therapeutics 7630.HK	Hong Kong	$325M	n/a	+395%	-173%	9.9×	n/a	n/a
Medtide 3880.HK	Hong Kong	$358M	-9%	+14%	36%	2.7×	n/a	n/a
Allogene Therapeutics ALLO	United States	$359M	-54%	-100%	-3,886%	22.8×	n/a	n/a
TransThera Sciences (Nanjing) 2617.HK	Hong Kong	$323M	-83%	n/a	-751%	36.4×	n/a	n/a
Agenus AGEN	United States	$323M	+87%	+30%	27%	4.4×	n/a	n/a
Aspen Neuroscience ASPE	United States	$362M	n/a	n/a	n/a	n/a	n/a	n/a
Zhejiang Laifual Drive 3952.HK	Hong Kong	$363M	n/a	+142%	-11%	7.1×	n/a	n/a
Lyell Immunopharma LYEL	United States	$364M	-23%	-55%	-729,281%	7,653.4×	n/a	n/a
Surrozen SRZN	United States	$364M	-35%	-9%	-385%	23.3×	n/a	n/a
Galectin Therapeutics GALT	United States	$317M	+50%	n/a	n/a	n/a	n/a	n/a
X4 Pharmaceuticals XFOR	United States	$315M	-28%	-52%	-555%	11.6×	n/a	n/a
G2GBIO 456160.KS	South Korea	$370M	-65%	-45%	-2,884%	775.0×	n/a	n/a
Medy-Tox 086900.KS	South Korea	$310M	-39%	+7%	7%	2.0×	6.0%	+11.9%

Questions

Which companies are Cuorips's closest peers?: The cockpit's peer set: Alector (ALEC), Fennec Pharmaceuticals (FENC), ProKidney (PROK), Benitec Biopharma (BNTC), AP Biosciences (6945.TWO), Viva Biotech (1873.HK), Laekna (2105.HK), IMPACT Therapeutics (7630.HK).
Is Cuorips expensive compared with its peers?: On ev / sales it trades at 392.1× against a peer median of 10.7×, 4th most expensive of 17 in its peer set.
How has Cuorips stock performed?: Over six months to 6 Nov 2026 the shares returned -9.2% against -28.2% for the median peer; over one year -10.9%.